In vitro studies on the pleotropic antidiabetic effects of zinc oxide nanoparticles

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 WHO. Fact file,10 facts about diabetes. www.who.int/features/factfiles/diabetes/facts/en/.
  Google Scholar
• 2 Pandey A, Tripathi P, Pandey R, Srivatava R, Goswami S. Alternative therapies useful in the management of diabetes: a systematic review. J. Pharm. Bioallied Sci. 3, 504–512 (2011).
  Medline CASGoogle Scholar
• 3 Prabhakar PK, Kumar A, Doble M. Combination therapy: a new strategy to manage diabetes and its complications. Phytomedicine 21, 123–130 (2014).
  Medline CASGoogle Scholar
• 4 Nakai M, Sekiguchi F, Obata M et al. Synthesis and insulin-mimetic activities of metal complexes with 3-hydroxypyridine-2-carboxylic acid. J. Inorg. Biochem. 99(6), 1275–1282 (2005).
  Medline CASGoogle Scholar
• 5 Barthel A, Ostrakhovitch EA, Walter PL, Kampkötter A, Klotz LO. Stimulation of phosphoinositide 3-kinase/Akt signaling by copper and zinc ions: mechanisms and consequences. Arch. Biochem. Biophys. 463(2), 175–182 (2007).
  Medline CASGoogle Scholar
• 6 Tripathi IP, Kumar MM, Arti K et al. Synthesis, characterization of some antidiabetic copper complexes with ethylenediamine. Res. J. Chem. Sci. 3(12), 54–59 (2013).
  CASGoogle Scholar
• 7 Thompson KH, Orvig C. Vanadium in diabetes: 100 years from Phase 0 to Phase I. J Inorg. Biochem. 100(12), 1925–1935 (2006).
  Medline CASGoogle Scholar
• 8 Sakurai H, Yoshikawa Y, Yasui H. Current state for the development of metallopharmaceutics and anti-diabetic metal complexes. Chem. Soc. Rev. 37(11), 2383–2392 (2008).
  Medline CASGoogle Scholar
• 9 Vardatsikos G, Mehdi MZ, Srivastava AK. Bis (maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes toits glucoregulatory responses. Int. J. Mol. Med. 24(3), 303–309 (2009).
  Medline CASGoogle Scholar
• 10 Fedorova EV, Buryakina AV, Zakharov AV, Filimonov DA, Lagunin AA, Poroikov VV. Design, synthesis and pharmacological evaluation of novel vanadium- containing complexes as antidiabetic agents. PLoS ONE 9(7), e100386 (2014).
  MedlineGoogle Scholar
• 11 Anderson RA. Chromium, glucose intolerance and diabetes. J. Am. Coll. Nutr. 17(6), 548–555 (1998).
  Medline CASGoogle Scholar
• 12 Martin J, Wang ZQ, Zhang XH et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with Type 2 diabetes. Diabetes Care 29(8), 1826–1832 (2006).
  Medline CASGoogle Scholar
• 13 Wang ZQ, Cefalu WT. Current concepts about chromium supplementation in Type 2 diabetes and insulin resistance. Curr. Diab. Rep. 10(2), 145–151 (2010).
  MedlineGoogle Scholar
• 14 El-Megharbel SM. Synthesis, characterization and antidiabetic activity of chromium (III) metformin complex. J. Microb. Biochem. Technol. 7, 65–75 (2015).
  CASGoogle Scholar
• 15 Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in Type 2 diabetic subjects a randomized double-blind controlled trial. Diabetes Care 26(4), 1147–1152 (2003).
  Medline CASGoogle Scholar
• 16 Yokota K, Kato M, Lister F et al. Clinical efficacy of magnesium supplementation in patients with Type 2 diabetes. J. Am. Coll. Nutr. 23(5), S506–S509 (2004).
  Medline CASGoogle Scholar
• 17 Tanko Y, Alhassan M, Mohammed KA et al. Modulatory role of magnesium and copper sulphates on serum lipid profile and serum liver enzymes in fructose-induced diabetic wistar rats. J. Appl. Pharm. Sci. 3(8), S64–S67 (2013).
  Google Scholar
• 18 Ayaz M, Can B, Ozdemir S, Turan B. Protective effect of selenium treatment on diabetes-induced myocardial structural alterations. Biol. Trace Elem. Res. 89(3), 215–226 (2002).
  Medline CASGoogle Scholar
• 19 Ayaz M, Ozdemir S, Ugur M, Vassort G, Turan B. Effects of selenium on altered mechanical and electrical cardiac activities of diabetic rat. Arch. Biochem. Biophys. 426(1), 83–90 (2004).
  Medline CASGoogle Scholar
• 20 Al-Quraishy S, Dkhil MA, Moneim AEA. Anti-hyperglycemic activity of selenium nanoparticles in streptozotocin-induced diabetic rats. Int. J. Nanomed. 10, 6741–6756 (2015).
  Medline CASGoogle Scholar
• 21 Vasudevan H, McNeill JH. Chronic cobalt treatment decreases hyperglycemia in streptozotocin-diabetic rats. Biometals 20(2), 129–134 (2007).
  Medline CASGoogle Scholar
• 22 Yang L, Crans DC, Miller SM et al. Cobalt (II) and cobalt (III) dipicolinate complexes: solid state, solution, and in vivo insulin-like properties. Inorg. Chem. 41(19), 4859–4871 (2002).
  Medline CASGoogle Scholar
• 23 Talba T, Shui XW, Cheng Q, Tian X. Antidiabetic effect of glucosaminic acid-cobalt (II) chelate in streptozotocin-induced diabetes in mice. Diabetes Metab. Syndr. Obes. 4, 137–140 (2011).
  Medline CASGoogle Scholar
• 24 Ho E, Quan N, Tsai YH, Lai W, Bray TM. Dietary zinc supplementation inhibits NF B activation and protects against chemically induced diabetes in CD1 mice. Exp. Biol. Med. 226(2), 103–111 (2001).
  CASGoogle Scholar
• 25 Ukperoro JU, Offiah N, Idris T, Awogoke D. Antioxidant effect of zinc, selenium and their combination on the liver and kidney of alloxan-induced diabetes in rats. Med. J. Nutrition. Metab. 3(1), 25–30 (2010).
  Google Scholar
• 26 Yoshikawa Y, Yasui H. Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry. Curr. Top. Med. Chem. 12, 210–218 (2012).
  Medline CASGoogle Scholar
• 27 Pandey G, Jain GC, Mathur N. Therapeutic potential of metals in managing diabetes mellitus: a review. J. Mol. Pathophysiol. 1(1), 63–76 (2012).
  Google Scholar
• 28 Chausmer AB. Zinc, insulin and diabetes. J. Am. Coll. Nutr. 17(2), 109–115 (1998).
  Medline CASGoogle Scholar
• 29 Kelleher SL, McCormick NH, Velasquez V, Lopez V. Zinc in specialized secretory tissues: roles in the pancreas, prostate, and mammary gland. Adv. Nutr. 2, 101–111 (2011).
  Medline CASGoogle Scholar
• 30 Huang L. Zinc and its transporters, pancreatic b-cells, and insulin metabolism. Vitam. Horm. 95, 365–90 (2014).
  Medline CASGoogle Scholar
• 31 Meyer JA, Spence DM. A perspective on the role of metals in diabetes: past findings and possible future directions. Metallomics 1(1), 32–41 (2009).
  CASGoogle Scholar
• 32 Liu Y, Batchuluun B, Ho L et al. Characterization of zinc influx transporters (ZIPs) in pancreatic β cells, roles in regulating cytosolic zinc homeostasis and insulin secretion. J. Biol. Chem. 290(30), 18757–18769 (2015).
  Medline CASGoogle Scholar
• 33 Mitchell RK, Hu M, Chabosseau PL et al. Molecular genetic regulation of Slc30a8/ZnT8 reveals a positive association with glucose tolerance. Mol. Endocrinol. 30(1), 77–91 (2015).
  MedlineGoogle Scholar
• 34 Smidt K, Jessen N, Petersen AB et al. SLC30A3 responds to glucose-and zinc variations in ß-cells and Is critical for insulin production and in vivo glucose-metabolism during ß-cell stress. PLoS ONE 4(5), e5684 (2009).
  MedlineGoogle Scholar
• 35 Chimienti F, Devergnas S, Pattou F et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J. Cell Sci. 119(20), 4199–4206 (2006).
  Medline CASGoogle Scholar
• 36 Kojima Y, Yoshikawa Y, Ueda E et al. Insulinomimetic zinc (II) complexes with natural products: in vitro evaluation and blood glucose lowering effect in KK-Ay mice with Type 2 diabetes mellitus. Chem. Pharm. Bull. 51(8), 1006–1008 (2003).
  Medline CASGoogle Scholar
• 37 Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals 18(4), 319–323 (2005).
  Medline CASGoogle Scholar
• 38 Ueda E, Yoshikawa Y, Sakurai H, Kojima Y, Kajiwara NM. In vitro alpha-glucosidase inhibitory effect of Zn (II) complex with 6-methyl-2-picolinmethylamide. Chem. Pharm. Bull. 53(4), 451–452 (2005).
  Medline CASGoogle Scholar
• 39 Sakurai H, Katoh A, Yoshikawa Y. Chemistry and biochemistry of insulin-mimetic vanadium and zinc complexes. Trial for treatment of diabetes mellitus. Bull. Chem. Soc. Jpn 79(11), 1645–1664 (2006).
  CASGoogle Scholar
• 40 Yoshikawa Y, Adachi Y, Sakurai H. A new type of orally active anti-diabetic Zn (II)-dithiocarbamate complex. Life Sci. 80(8), 759–766 (2007).
  Medline CASGoogle Scholar
• 41 Nakayama A, Hiromura M, Adachi Y, Sakurai H. Molecular mechanism of antidiabetic zinc–allixin complexes: regulations of glucose utilization and lipid metabolism. J. Biol. Inorg. Chem. 13(5), 675–684 (2008). •• One of the earliest detailed report on effects of zinc on lipid metabolism.
  Medline CASGoogle Scholar
• 42 Capdor J, Foster M, Petocz P, Samman S. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J. Trace Elem. Med. Biol. 27, 137–142 (2013).
  Medline CASGoogle Scholar
• 43 Marchesini G, Bugianesi E, Ronchi M, Flamia R, Thomaseth K, Pacini G. Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism 47(7), 792–798 (1998).
  Medline CASGoogle Scholar
• 44 Alkaladi A, Abdelazim AM, Afifi M. Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats. Int. J. Mol. Sci. 15, 2015–2023 (2014).
  MedlineGoogle Scholar
• 45 Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F. Effect of zinc sulfate supplementation on lipid and glucose in Type 2 diabetic patients. Pak. J. Nutr. 7(4), 550–553 (2008).
  CASGoogle Scholar
• 46 Hashemipour M, Kelishadi R, Shapouri J et al. Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children. Hormones (Athens). 8(4), 279–285 (2009).
  MedlineGoogle Scholar
• 47 Gunasekara P, Hettiarachchi M, Liyanage C, Lekamwasam S. Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes. Diabetes Metab. Syndr. Obes. 4, 53–60 (2011).
  Medline CASGoogle Scholar
• 48 Karamali M, Heidarzadeh Z, Seifati SM et al. Zinc supplementation and the effects on metabolic status in gestational diabetes: a randomized, double-blind, placebo-controlled trial. J. Diabetes Complicat. 29(8), 1314–1319 (2015).
  MedlineGoogle Scholar
• 49 Umrani RD, Paknikar KM. Zinc oxide nanoparticles show antidiabetic activity in streptozotocin-induced Types 1 and 2 diabetic rats. Nanomedicine 9(1), 89–104 (2014).
  CASGoogle Scholar
• 50 Bianchi GP, Marchesini G, Brizi M et al. 2000. Nutritional effects of oral zinc supplementation in cirrhosis. Nutr. Res. 20(8), 1079–1089 (2000).
  CASGoogle Scholar
• 51 Mocchegiani E, Malavolta M, Giacconi R, Costarelli L. Dietary Intake and impact of zinc supplementation on the immune functions in elderly: nutrigenomic approach. In: Immunology of Aging. Massoud A, Rezaei N (Eds). Springer Verlag, Berlin-Heidelberg, Germany, 295–308 (2014).
  Google Scholar
• 52 Mocchegiani E, Romeo J, Malavolta M et al. Zinc: dietary intake and impact of supplementation on immune function in elderly. Age 35(3), 839–860 (2013).
  Medline CASGoogle Scholar
• 53 Obanda DN, Cefalu WT. Modulation of cellular insulin signaling and PTP1B effects by lipid metabolites in skeletal muscle cells. J. Nutr. Biochem. 24(8), 1529–1537 (2013).
  Medline CASGoogle Scholar
• 54 Bakke J, Haj FG. Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin. Cell. Dev. Biol. 37, 58–65 (2015).
  Medline CASGoogle Scholar
• 55 Wilson M, Hogstrand C, Maret W. Picomolar concentrations of free zinc(II) ions regulate receptor protein tyrosine phosphatase beta activity. J. Biol. Chem. 287(12), 9322–9326 (2012).
  Medline CASGoogle Scholar
• 56 Bellomo E, Massarotti A, Hogstrand C, Maret W. Zinc ions modulate protein tyrosine phosphatase 1B activity. Metallomics 6, 1229–1239 (2014). •• Reports PTP1B regulation by zinc ions.
  Medline CASGoogle Scholar
• 57 Naito Y, Yoshikawa Y, Yasui H. Cellular mechanism of zinc-hinokitiol complexes in diabetes mellitus. Bull. Chem. Soc. Jpn. 84(3), 298–305 (2011). •• A report on effects of zinc complex on PKB phosphorylation, GLUT4 translocation and glucose uptake.
  CASGoogle Scholar
• 58 Olson AL. Regulation of GLUT4 and insulin-dependent glucose flux. ISRN Mol Bio. 2012, 856987 (2012).
  MedlineGoogle Scholar
• 59 Lai YC, Liu Y, Jacobs R, Ridera MH. A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle. Biochem. J. 447, 137–147 (2012).
  Medline CASGoogle Scholar
• 60 Huang S, Czech MP. The GLUT4 glucose transporter. Cell. Metab. 5(4), 237–252 (2007).
  Medline CASGoogle Scholar
• 61 Morgan BJ, Chai SY, Albiston AL. GLUT4 associated proteins as therapeutic targets for diabetes. Recent. Pat. Endocr. Metab. Immune Drug. Discov. 5, 25–32 (2011).
  Medline CASGoogle Scholar
• 62 Kim DH, Perdomo G, Zhang T. FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes 60, 2763–2774 (2013).
  Google Scholar
• 63 Guan HP, Chen G. Factors affecting insulin regulated hepatic gene expression. In: Progress in Molecular Biology and Translational Science: Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus (Volume 121). Ya-Xiong T (Ed.). Academic Press, Cambridge, USA, 165–215 (2014). • Describes in detail the insulin's regulation of gluconeogenesis.
  Google Scholar
• 64 Rutman JZ, Rutman RJ, George P. The influence of metal ions on the denovo synthesis of glucose by rat kidney cortex slices. Life Sci. 3(6), 617–624 (1964). • Primary evidence for role of metals ions in gluconeogenesis.
  Medline CASGoogle Scholar
• 65 Cameron AR, Wallace K, Logie L et al. The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. Biochem. J. 443, 57–64 (2012).
  Medline CASGoogle Scholar
• 66 Stinkens R, Goossens GH, Jocken JW, Blaak EE. Targeting fatty acid metabolism to improve glucose metabolism. Obes. Rev. 16(9), 715–57 (2015).
  Medline CASGoogle Scholar
• 67 Moon MH, Jeong JK, Lee YJ et al. 18β-glycyrrhetinic acid inhibits adipogenic differentiation and stimulates lipolysis. Biochem. Biophys. Res. Commun. 420, 805–810 (2012).
  Medline CASGoogle Scholar
• 68 Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 14(121), 1–9 (2015).
  MedlineGoogle Scholar
• 69 Zhang HB, Wang MS, Wang ZS et al. Supplementation dietary zinc levels on growth performance, carcass traits, and intramuscular fat deposition in weaned piglets. Biol. Trace Elem. Res. 161(1), 69–77 (2014).
  Medline CASGoogle Scholar
• 70 Maxel T, Smidt K, Larsen A et al. Gene expression of the zinc transporter ZIP14 (SLC39a14) is affected by weight loss and metabolic status and associates with PPARγ in human adipose tissue and 3T3-L1 pre-adipocytes. BMC Obes. 2(1), 1–11 (2015).
  MedlineGoogle Scholar
• 71 Meier JJ, Bonadonna RC. Role of reduced β-cell mass versus impaired β-cell function in the pathogenesis of Type 2 diabetes. Diabetes Care 36(2), 113–119 (2013).
  Google Scholar
• 72 Sharma V, Anderson D, Dhawan A. Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2). Apoptosis 17, 852–870 (2012).
  Medline CASGoogle Scholar
• 73 Sharma V, Singh P, Pandey AK, Dhawan A. Induction of oxidative stress, DNA damage and apoptosis in mouse liver after sub-acute oral exposure to zinc oxide nanoparticles. Mutat. Res. 745, 84–91 (2012).
  Medline CASGoogle Scholar
• 74 Baek M, Kim MK, Cho HJ et al. Factors influencing the cytotoxicity of zinc oxide nanoparticles: particle size and surface charge. J. Phys. 304, 012044 (2011). •• Provides evidence on effects of size and charge on cytotoxicity of zinc oxide nanoparticles.
  Google Scholar
• 75 Luo M, Shen C, Feltis BN et al. Reducing ZnO nanoparticle cytotoxicity by surface modification. Nanoscale 6, 5791–5798 (2014).
  Medline CASGoogle Scholar
• 76 Muthuraman P, Ramkumar K, Kim DH. Analysis of dose-dependent effect of zinc oxide nanoparticles on the oxidative stress and antioxidant enzyme activity in adipocytes. Appl. Biochem. Biotechnol. 174, 2851–2863 (2014). •• Elucidates the cytotoxic and safe concentrations of zinc oxide nanoparticles.
  Medline CASGoogle Scholar
• 77 Taccola L, Raffa V, Riggio C et al. Zinc oxide nanoparticles as selective killers of proliferating cells. Int. J. Nanomed. 6, 1129–1140 (2011).
  Medline CASGoogle Scholar
• 78 Das D, Nath BC, Phukon P, Dolui SK. Synthesis of ZnO nanoparticles and evaluation of antioxidant and cytotoxic activity. Colloids Surf. B Biointerfaces 111, 556–560 (2013).
  Medline CASGoogle Scholar
• 79 Nagajyothi PC, Cha SJ, Yang IJ, Sreekanth TV, Kim KJ, Shin HM. Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract. J. Photochem. Photobiol. B Biol. 146, 10–17 (2015).
  Medline CASGoogle Scholar